Cytomx Therapeutics, Inc.2024财年第二财季实现净利润-6.53百万美元，同比减少499.08%

自选股智能写手08-18

8月18日，Cytomx Therapeutics, Inc.（CTMX.US）公布财报，公告显示公司2024财年第二财季净利润为-6.53百万美元，同比减少499.08%；其中营业收入为25.12百万美元，同比增加1.62%，每股基本收益为-0.08美元。从资产负债表来看，Cytomx Therapeutics, Inc.（CTMX.US）总负债1.90亿美元，其中短期债务4.86百万美元，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2460735033?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-18 00:03","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2460735033","market":"us","top_or_hot":-1,"title":"Cytomx Therapeutics, Inc.2024财年第二财季实现净利润-6.53百万美元，同比减少499.08%","media":"自选股智能写手","content":"<div>\n<p>8月18日，Cytomx Therapeutics, Inc.（CTMX.US）公布财报，公告显示公司2024财年第二财季净利润为-6.53百万美元，同比减少499.08%；其中营业收入为25.12百万美元，同比增加1.62%，每股基本收益为-0.08美元。从资产负债表来看，Cytomx Therapeutics, Inc.（CTMX.US）总负债1.90亿美元，其中短期债务4.86百万美元，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081800055795a1673b&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cytomx Therapeutics, Inc.2024财年第二财季实现净利润-6.53百万美元，同比减少499.08%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCytomx Therapeutics, Inc.2024财年第二财季实现净利润-6.53百万美元，同比减少499.08%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-18 00:03 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081800055795a1673b&s=b><strong>自选股智能写手</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月18日，Cytomx Therapeutics, Inc.（CTMX.US）公布财报，公告显示公司2024财年第二财季净利润为-6.53百万美元，同比减少499.08%；其中营业收入为25.12百万美元，同比增加1.62%，每股基本收益为-0.08美元。从资产负债表来看，Cytomx Therapeutics, Inc.（CTMX.US）总负债1.90亿美元，其中短期债务4.86百万美元，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081800055795a1673b&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081800055795a1673b&s=b","article_id":"2460735033","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081800055795a1673b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2460735033","pubTimestamp":1723910629,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"8月18日，Cytomx Therapeutics, Inc.公布财报，公告显示公司2024财年第二财季净利润为-6.53百万美元，同比减少499.08%；其中营业收入为25.12百万美元，同比增加1.62%，每股基本收益为-0.08美元。从资产负债表来看，Cytomx Therapeutics, Inc.总负债1.90亿美元，其中短期债务4.86百万美元，资产负债比为0.84，流动比率为1.00。机构评级：截至2024年8月18日，当前有5家机构对Cytomx Therapeutics, Inc.目标价做出预测，其中目标均价为5.31美元，其中最低目标价为3.50美元，最高目标价为8.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"LENZ":"Therapeutics","CTMX":"CytomX"},"translate_title":"Cytomx Therapeutics, Inc. achieved net profit of-US $6.53 million in the second fiscal quarter of fiscal 2024, a year-on-year decrease of 499.08%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTMX":1,"LENZ":1},"content_text":"8月18日，Cytomx Therapeutics, Inc.（CTMX.US）公布财报，公告显示公司2024财年第二财季净利润为-6.53百万美元，同比减少499.08%；其中营业收入为25.12百万美元，同比增加1.62%，每股基本收益为-0.08美元。从资产负债表来看，Cytomx Therapeutics, Inc.（CTMX.US）总负债1.90亿美元，其中短期债务4.86百万美元，资产负债比为0.84，流动比率为1.00。机构评级：截至2024年8月18日，当前有5家机构对Cytomx Therapeutics, Inc.目标价做出预测，其中目标均价为5.31美元，其中最低目标价为3.50美元，最高目标价为8.00美元。公司简介：CytomX Therapeutics Inc 是一家在美国运营的专注于肿瘤学的生物制药公司。 该公司致力于开发基于probody技术平台的抗体疗法。 该公司的probody技术平台针对临床验证的靶点创建专有的癌症免疫疗法，并开发癌症疗法。probody疗法旨在利用肿瘤微环境中的条件来增强抗体的肿瘤靶向特性并降低健康组织中的药物活性。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2460735033"}